Insider · CIK 0001849189
Ilan Levin
Files at SLXN (Silexion Therapeutics Corp). First filing -, latest -.
In brief
Ilan Levin files SEC Form 4 as director and 10% owner at SLXN (Silexion Therapeutics Corp). No open-market trade is on file; the transactions below are grants, exercises and other rows that carry no view on the price.
A track record needs three past buys with six months of prices behind them; Ilan Levin has 0, so none is measured yet.
Signals
This insider’s open-market buys and sells, scored.
Transactions
Every row this insider has filed, 3 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Aug 7, 2025 | SLXN Silexion Therapeutics Corp | JOther Ordinary Sharesindirect: By Moringa Sponsor, LP. | -5,550 | $0.00 | $0 | 6,970 | Jan 27, 2026 |
| Sep 15, 2025 | SLXN Silexion Therapeutics Corp | AGrant or award Ordinary Sharesindirect: By Moringa Sponsor, LP. | +450,000 | $4.00 | $1.8M | 456,970 | Jan 27, 2026 |
| Aug 7, 2025 | SLXN Silexion Therapeutics Corp | JOther Warrant (right to buy)derivativeindirect: By Moringa Sponsor, LP. | -935 | $0.00 | $0 | 372 | Jan 27, 2026 |
Questions about Ilan Levin
Answered from the filings on this page, as of the latest one.
Is Ilan Levin buying or selling?
Ilan Levin has no open-market buy or sell on SEC Form 4; the filings on record are grants, exercises and other transactions.
How did Ilan Levin's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Ilan Levin has 0.
Where does Ilan Levin file Form 4?
Ilan Levin has filed Form 4 at SLXN (Silexion Therapeutics Corp). A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.